Liminatus Pharma, Inc. — Form 8-K
Filed July 24, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
On July 20, 2026, Liminatus Pharma received notice of delisting or failure to satisfy continued listing rules/standards, with transfer of listing noted. The filing provides no specific details on the reason for delisting notice, the exchange involved, cure period, or remedial actions. The 8-K discloses the event under Items 3.01 and 8.01 but contains no quantified financial impact or timeline.
Why this rating
Delisting threat is existential risk for public company regardless of size; threatens market access, liquidity, and shareholder value materially.
Extracted items
- 3.01 delisting notice
- 8.01 other event
- 9.01 exhibits
See more from July 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.